ASH 2020 Highlights - GvHD

ASH 2020 Highlights - GvHD

A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant

Transplant-associated thrombotic microangiopathy is a severe complication of hematopoietic stem cell transplantation.

Blood Advances
Podcast: ASH 2020 Top Science

Among the research at this year's ASH virtual meeting, investigators presented noteworthy findings on an innovative gene therapy for sickle cell disease, CAR T-cell therapy...

MedPage Today
ALLO-715 Found to Be Effective Against Multiple Myeloma

ALL0-715 is a genetically modified anti-BCMA AlloCAR T cell product in which the TCR alpha constant gene is disrupted in order to reduce the risk of graft-versus-host disease.


In Utero Hematopoietic Cell Transplantation Safe in Fetuses with Alpha Thalassemia Major

In utero hematopoietic cell transplantation with maternal cells was safe in two fetuses with alpha thalassemia major, according to interim results of a phase I clinical trial.


Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders

Men at Increased Risk for Mortality Following Allogeneic Hematopoietic Stem Cell Transplant

GVHD and age at transplant were significantly associated with mortality risk.

Cancer Therapy Advisor
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Investigators conducted a multicenter proof-of-concept “preemptive” treatment trial of α-1-antitrypsin, a serine protease inhibitor with demonstrated activity against GVHD, in patients...

Blood Advances
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

This study investigated cyclosporine-A/mycophenolate mofetil–based intermediate intensity unmanipulated double-unit CBT with prioritization of unit quality and CD34+ cell dose in graft selection.

Blood Advances
ASH 2020: Ruxolitinib for Steroid-Refractory/Steroid-Dependent Chronic Graft-vs-Host Disease

Ruxolitinib was superior to best available therapy in achieving efficacy as determined by overall response and duration of response, with acceptable safety in adolescents and adults with...

The ASCO Post
Next-generation cell therapies: the emerging role of CAR-NK cells

T cells engineered with CARs have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies.

Blood Advances
Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis

This study describes aggregate results of remestemcel-L treatment of SR-aGVHD in the pediatric population.

Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients

Acute graft-versus-host disease is a leading cause of transplantation-related mortality after allogeneic hematopoietic stem cell transplantation.

Blood Advances
Mesenchymal stromal cells in hematopoietic cell transplantation

This study reviews key historical data in the context of the most salient recent findings to present the current state of MSCs as adjunct cell therapy in hematopoietic cell transplantation.

Blood Advances
Orca-T Shows Preventative Potential for GVHS in High-Risk Blood Cancers

The precision Treg-engineered donor product Orca-T exhibited preventive potential for GVHD in patients with high-risk hematologic malignancies who underwent HSCT...

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.

However as the infused lymphocytes are not selected for leukemia-specificity, the GVL effect is often accompanied by life-threatening GVHD due to the concurrent transfer of allo-reactive lymphocyte

Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome

Allo-HCT presents a novel approach to treat refractory DM in patients with a coexisting malignancy through the GvA effect.

Blood Advances
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

This study investigated the efficacy and safety of azacitidine maintenance in the posttransplant setting based on the encouraging phase 1/2 reports for azacitidine maintenance in patients...

Blood Advances
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients

Virus-specific T cells against BKPyV are safe with no infusional toxicity, de novo graft-versus-host disease, or graft rejection.

Blood Advances
CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation

In this retrospective analysis, it is demonstrated that early CD4+ IR is associated with survival after moderate to severe aGvHD.

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

This study investigated the clinical efficacy of ruxolitinib and its safety profile in patients having SR-cGVHD after allo-SCT during the treatment course.

Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India

This study investigates the experience with etanercept as the initial agent in SR aGVHD.

Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis

Pre-transplant comorbidities, which may impact the success of allogeneic stem cell transplantation can be appreciated through 3 different scoring systems.


source list reference